A study published in January 2022 evaluated the risk for newly diagnosed diabetes after infection with Covid-19 between March 1, 2020, and June 28, 2021, among persons aged less than 18 years. The data came from two U.S. medical claims databases, IQVIA and HealthVerity. A group consisted of individuals with a diagnosed Covid-19 infection who were assessed for the risk of a new diagnosis of diabetes (type 1, type 2, or other diabetes) within 30 days of a diagnosis of a Covid-19 infection (Covid-19 individuals). The other group consisted of individuals without a diagnosis of a Covid-19 infection between March 1, 2020, and June 28, 2021, and assessed for the risk of a new diagnosis of diabetes (Non-Covid-19 individuals). All individuals had to be continuously enrolled in the medical systems throughout the study period. A subset of the study results is reported in the table below. Covid-19 individuals Non-Covid-19 individuals No. newly diagnosed Cases per No. newly diagnosed Cases per Database diabetes/Person-Years 100000 diabetes/Person-Years 100000 Person-years Person-years IQVIA 68/21,563 315 132/111,418 118 HealthVerity 1120/280,767 399 853/281,072 30318. Fill in the rate differences and rate ratios in the table below. Database Rate ratio Rate difference (Covid-19 \\ Non-Covid-19) (Covid-19 - Non-Covid-19) IQVIA HealthVerity